{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:28:03Z","timestamp":1757701683105,"version":"3.37.3"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100018911","name":"University Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Heart disease is recognized as the leading cause of morbidity and mortality in patients with muscular dystrophy (MD). Our study demonstrates the clinical utility of cardiac biomarkers to improve the diagnosis of cardiomyopathy and prognostication of major adverse cardiac events (MACE) in these vulnerable patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We prospectively followed 117 patients [median age, 42 [interquartile range (IQR), 26\u201350) years; 49 (41.9%) women] at the Neuromuscular Multidisciplinary clinic diagnosed with a dystrophinopathy, limb-girdle MD, type 1 myotonic dystrophy, or facioscapulohumeral MD. We determined that B-type natriuretic peptide (BNP) and high-sensitive troponin I (hsTnI) were effective diagnostic markers of cardiomyopathy [area under the curve (AUC), 0.64; P\u2009=\u20090.017; and AUC, 0.69; P\u2009=\u20090.001, respectively]. Patient risk stratification for MACE was based on cut-off values of BNP and hsTnI defined a priori as 30.5000\u2009pg\/mL and 7.6050\u2009ng\/L, respectively. Over a median follow-up period of 2.09 (IQR, 1.17\u20132.81) years there were 36 confirmed MACE. Multivariate regression analyses showed that patients with BNP and hsTnI levels above the respective cut-off values had a 3.70-fold (P\u2009=\u20090.001) and 3.24-fold (P\u2009=\u20090.002) greater risk of MACE, respectively, compared with patients with biomarker levels below. Furthermore, patients with biomarker levels above both cut-off values had a 4.08-fold (P\u2009=\u20090.001) greater risk of MACE. Inflammatory biomarkers did not show clinical utility for heart disease in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study demonstrates important diagnostic and prognostic value of BNP and hsTnI as part of a comprehensive cardiac assessment to augment the management and treatment of heart disease in patients with MD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcaa059","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T03:30:42Z","timestamp":1594783842000},"page":"564-573","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating the diagnostic and prognostic value of biomarkers for heart disease and major adverse cardiac events in patients with muscular dystrophy"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-4907","authenticated-orcid":false,"given":"Anish","family":"Nikhanj","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta T6G 2S2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bailey","family":"Miskew Nichols","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta T6G 2S2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiming","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta T6G 2S2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaeem A","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-9028","authenticated-orcid":false,"given":"Gavin Y","family":"Oudit","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta T6G 2S2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"2021103112205071200_qcaa059-B1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.hrthm.2012.06.032","article-title":"Assessment of cardiac involvement in myotonic muscular dystrophy by T1 mapping on magnetic resonance imaging","volume":"9","author":"Turkbey","year":"2012","journal-title":"Heart Rhythm"},{"key":"2021103112205071200_qcaa059-B2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/0735-1097(94)90116-3","article-title":"Cardiomyopathy of limb-girdle muscular dystrophy","volume":"24","author":"Mascarenhas","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2021103112205071200_qcaa059-B3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12968-016-0281-y","article-title":"Myocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers","volume":"18","author":"Wexberg","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"2021103112205071200_qcaa059-B4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"2021103112205071200_qcaa059-B5","doi-asserted-by":"crossref","first-page":"e014004","DOI":"10.1161\/JAHA.119.014004","article-title":"Cardiac intervention improves heart disease and clinical outcomes in patients with muscular dystrophy in a multidisciplinary care setting","volume":"9","author":"Nikhanj","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2021103112205071200_qcaa059-B6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"2021103112205071200_qcaa059-B7","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1056\/NEJMoa062800","article-title":"Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1","volume":"358","author":"Groh","year":"2008","journal-title":"N Engl J Med"},{"key":"2021103112205071200_qcaa059-B8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jama.2012.6807","article-title":"Arrhythmia management in myotonic dystrophy type 1","volume":"308","author":"Groh","year":"2012","journal-title":"JAMA"},{"key":"2021103112205071200_qcaa059-B9","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021103112205071200_qcaa059-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-016-0019-0","article-title":"Inflammatory predisposition predicts disease phenotypes in muscular dystrophy","volume":"36","author":"Nitahara-Kasahara","year":"2016","journal-title":"Inflamm Regen"},{"key":"2021103112205071200_qcaa059-B11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"2021103112205071200_qcaa059-B12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","article-title":"Normal values for cardiovascular magnetic resonance in adults and children","volume":"17","author":"Kawel-Boehm","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"2021103112205071200_qcaa059-B13","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2021103112205071200_qcaa059-B14","first-page":"299","article-title":"Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study","volume":"36","author":"Bionda","year":"2006","journal-title":"Ann Clin Lab Sci"},{"key":"2021103112205071200_qcaa059-B15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1373\/clinchem.2018.300061","article-title":"High-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarction","volume":"65","author":"Boeddinghaus","year":"2019","journal-title":"Clin Chem"},{"key":"2021103112205071200_qcaa059-B16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ehjqcco\/qcx034","article-title":"Troponin measurement in patients with suspected acute coronary syndromes: walking beyond the wall","volume":"4","author":"Collinson","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2021103112205071200_qcaa059-B17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ehjqcco\/qcx022","article-title":"High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study","volume":"4","author":"Stelzle","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2021103112205071200_qcaa059-B18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/cem.2018.435","article-title":"Sex-specific, high-sensitivity cardiac troponin T cut-off concentrations for ruling out acute myocardial infarction with a single measurement","volume":"21","author":"McRae","year":"2019","journal-title":"CJEM"},{"key":"2021103112205071200_qcaa059-B19","doi-asserted-by":"crossref","first-page":"e0187662","DOI":"10.1371\/journal.pone.0187662","article-title":"Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department","volume":"12","author":"Ambavane","year":"2017","journal-title":"PLoS One"},{"key":"2021103112205071200_qcaa059-B20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ehjqcco\/qcv033","article-title":"Prognostic value of high sensitivity troponin T after ST-segment elevation myocardial infarction in the era of cardiac magnetic resonance imaging","volume":"2","author":"Nguyen","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2021103112205071200_qcaa059-B21","doi-asserted-by":"crossref","first-page":"e009098","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2021103112205071200_qcaa059-B22","doi-asserted-by":"crossref","first-page":"e99495","DOI":"10.1371\/journal.pone.0099495","article-title":"Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology","volume":"9","author":"Putko","year":"2014","journal-title":"PLoS One"},{"key":"2021103112205071200_qcaa059-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3762651","article-title":"Defining an optimal cut-point value in ROC analysis: an alternative approach","volume":"2017","author":"Unal","year":"2017","journal-title":"Comput Math Methods Med"},{"key":"2021103112205071200_qcaa059-B24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2021103112205071200_qcaa059-B25","doi-asserted-by":"crossref","first-page":"e006541","DOI":"10.1161\/CIRCHEARTFAILURE.119.006541","article-title":"Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction","volume":"13","author":"R\u00f8rth","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2021103112205071200_qcaa059-B26","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2021103112205071200_qcaa059-B27","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.4081\/ni.2018.7917","article-title":"Accuracy of B-natriuretic peptide for the diagnosis of decompensated heart failure in muscular dystrophies patients with chronic respiratory failure","volume":"10","author":"Meng","year":"2018","journal-title":"Neurol Int"},{"key":"2021103112205071200_qcaa059-B28","doi-asserted-by":"crossref","first-page":"030501","DOI":"10.11613\/BM.2018.030501","article-title":"\u201cUltra-sensitive\u201d cardiac troponins: requirements for effective implementation in clinical practice","volume":"28","author":"Lippi","year":"2018","journal-title":"Biochem Med (Zagreb)"},{"key":"2021103112205071200_qcaa059-B29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.106.655076","article-title":"Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure","volume":"116","author":"Latini","year":"2007","journal-title":"Circulation"},{"key":"2021103112205071200_qcaa059-B30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCHEARTFAILURE.111.961581","article-title":"Impact of serial troponin release on outcomes in patients with acute heart failure","volume":"4","author":"O'Connor","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2021103112205071200_qcaa059-B31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fcvm.2017.00082","article-title":"Echocardiographic image quality deteriorates with age in children and young adults with Duchenne muscular dystrophy","volume":"4","author":"Power","year":"2017","journal-title":"Front Cardiovasc Med"},{"key":"2021103112205071200_qcaa059-B32","first-page":"e240","article-title":"2013 ACCF\/AHA Guideline for the management of heart failure","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2021103112205071200_qcaa059-B33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.echo.2014.11.018","article-title":"Global longitudinal strain and global circumferential strain by speckle-tracking echocardiography and feature-tracking cardiac magnetic resonance imaging: comparison with left ventricular ejection fraction","volume":"28","author":"Onishi","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2021103112205071200_qcaa059-B34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jacc.2008.12.032","article-title":"Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study","volume":"53","author":"Hor","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2021103112205071200_qcaa059-B35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.ede.0000147512.81966.ba","article-title":"Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples","volume":"16","author":"Schisterman","year":"2005","journal-title":"Epidemiology"},{"key":"2021103112205071200_qcaa059-B36","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1161\/CIRCULATIONAHA.114.014245","article-title":"Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction","volume":"131","author":"Twerenbold","year":"2015","journal-title":"Circulation"},{"key":"2021103112205071200_qcaa059-B37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamacardio.2016.4910","article-title":"Cardiomyopathy in muscular dystrophy: when to treat?","volume":"2","author":"McNally","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2021103112205071200_qcaa059-B38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJM198705073161906","article-title":"Practical problems in the respiratory care of patients with muscular dystrophy","volume":"316","author":"Smith","year":"1987","journal-title":"N Engl J Med"},{"key":"2021103112205071200_qcaa059-B39","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1542\/peds.2018-0333H","article-title":"Respiratory management of the patient with Duchenne muscular dystrophy","volume":"142","author":"Sheehan","year":"2018","journal-title":"Pediatrics"},{"key":"2021103112205071200_qcaa059-B40","doi-asserted-by":"crossref","first-page":"e0153095","DOI":"10.1371\/journal.pone.0153095","article-title":"Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D","volume":"11","author":"Fayssoil","year":"2016","journal-title":"PLoS One"},{"key":"2021103112205071200_qcaa059-B41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/CIRCULATIONAHA.119.042960","article-title":"High-sensitivity cardiac troponin and the universal definition of myocardial infarction","volume":"141","author":"Chapman","year":"2020","journal-title":"Circulation"},{"key":"2021103112205071200_qcaa059-B42","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.118.038358","article-title":"Type natriuretic peptides and cardiac troponins for diagnosis and risk-stratification of syncope","volume":"139","author":"Du Fay de Lavallaz","year":"2019","journal-title":"Circulation"},{"key":"2021103112205071200_qcaa059-B43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2019.05.012","article-title":"Short-term follow-up BNP level and risk stratification after myocardial infarction","volume":"291","author":"Be\u0142towski","year":"2019","journal-title":"Int J Cardiol"},{"key":"2021103112205071200_qcaa059-B44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jama.1996.03530410049032","article-title":"Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies","volume":"275","author":"Politano","year":"1996","journal-title":"JAMA"},{"key":"2021103112205071200_qcaa059-B45","doi-asserted-by":"crossref","first-page":"ytz095","DOI":"10.1093\/ehjcr\/ytz095","article-title":"Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series","volume":"3","author":"Nikhanj","year":"2019","journal-title":"Eur Heart J Case Rep"},{"key":"2021103112205071200_qcaa059-B46","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.amjcard.2019.08.039","article-title":"Comparison of usefulness of cardiac resynchronization therapy in patients with type 1 myotonic dystrophy with versus without left bundle branch block","volume":"124","author":"Nikhanj","year":"2019","journal-title":"Am J Cardiol"},{"key":"2021103112205071200_qcaa059-B47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejheart.2005.01.022","article-title":"The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study","volume":"7","author":"Zaphiriou","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2021103112205071200_qcaa059-B48","doi-asserted-by":"crossref","first-page":"e006340","DOI":"10.1161\/JAHA.117.006340","article-title":"Predictors of death in adults with Duchenne muscular dystrophy\u2013associated cardiomyopathy","volume":"6","author":"Cheeran","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021103112205071200_qcaa059-B49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamacardio.2016.1309","article-title":"Evaluation of high-sensitivity cardiac troponin I levels in patients with suspected acute coronary syndrome","volume":"1","author":"Carlton","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2021103112205071200_qcaa059-B50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaneurol.2017.4778","article-title":"Development and validation of a new scoring system to predict survival in patients with myotonic dystrophy type 1","volume":"75","author":"Wahbi","year":"2018","journal-title":"JAMA Neurol"},{"key":"2021103112205071200_qcaa059-B51","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaa059\/33676623\/qcaa059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjqcco\/article-pdf\/7\/6\/564\/40947435\/qcaa059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjqcco\/article-pdf\/7\/6\/564\/40947435\/qcaa059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T12:29:39Z","timestamp":1635683379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/7\/6\/564\/5873870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,7,20]]},"published-print":{"date-parts":[[2021,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa059","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"type":"print","value":"2058-5225"},{"type":"electronic","value":"2058-1742"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2020,7,20]]}}}